Today is one of those special days in the saga of everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY). A day where The NaDDir* issued not one, not two, but three, ridiculous press releases seemingly devoid of substance.

But only seemingly.

Compare the boilerplate about Cytodyn’s ill-fated BLA re-submission for loserlimab in HIV from last week:

to the new boilerplate from today’s nonsense:

Oops. There it is, the one little bit of real information they tried to bury under a pile of bullshit. That pivot to a ridiculous cancer cure cannot come soon enough for the Klown Krew.

* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.